Immune Clinical Trials

567 recruitingLast updated: July 25, 2026

There are 567 actively recruiting immune clinical trials across 57 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3, Phase 4. Top locations include Beijing, Beijing Municipality, China, Tianjin, Tianjin Municipality, China, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Immune Trials at a Glance

567 actively recruiting trials for immune are listed on ClinicalTrialsFinder across 6 cities in 57 countries. The largest study group is Phase 2 with 135 trials, with the heaviest enrollment activity in Beijing, Tianjin, and Bethesda. Lead sponsors running immune studies include Institute of Hematology & Blood Diseases Hospital, China, National Institute of Allergy and Infectious Diseases (NIAID), and Assistance Publique - Hôpitaux de Paris.

Treatments under study

About Immune Clinical Trials

Looking for clinical trials for Immune? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 567 trials

Recruiting

Deciphering the Genetic Architecture of Autoimmune Diseases

Autoimmune Diseases
National Human Genome Research Institute (NHGRI)300 enrolled2 locationsNCT06948110
Recruiting
Phase 3

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC39 enrolled21 locationsNCT06449651
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled77 locationsNCT06371417
Recruiting
Not Applicable

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

PancreatitisType 1 Diabetes (T1D)Latent Autoimmune Diabetes in Adult (LADA)
Yale University60 enrolled1 locationNCT06967701
Recruiting

PET Imaging and Lymph Node Assessment of IRIS in People With AIDS

Immune Reconstitution Inflammatory Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT02147405
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

Primary Immune Deficiency
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled7 locationsNCT00246857
Recruiting
Phase 1

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.100 enrolled8 locationsNCT06680037
Recruiting

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Immune System DiseasesEosinophiliaHelminthiasis+2 more
National Institute of Allergy and Infectious Diseases (NIAID)800 enrolled1 locationNCT00001406
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

PneumoniaInfectionsImmune System Diseases+2 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00006150
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting
Phase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Warm Autoimmune Hemolytic AnemiaPrimary immune thrombocytopenia
Novartis Pharmaceuticals60 enrolled25 locationsNCT07039422
Recruiting
Phase 1Phase 2

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

Immune Thrombocytopenic PurpuraITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more
CRISPR Therapeutics AG60 enrolled8 locationsNCT07549698
Recruiting

Detection and Characterization of Infections and Infection Susceptibility

Immune Deficiencies
National Institute of Allergy and Infectious Diseases (NIAID)2,000 enrolled1 locationNCT00404560
Recruiting
Not Applicable

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

heart transplant rejectionPatient EngagementHealth Behavior+4 more
University of Florida100 enrolled4 locationsNCT05732779
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting
Phase 1

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Vaccine ResponseImmune Response to Covid 19 VaccinationCOVID-19 vaccine
The Methodist Hospital Research Institute75 enrolled1 locationNCT06821100
Recruiting
Phase 1

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins16 enrolled1 locationNCT07424222